Frankfurt - Delayed Quote EUR

Haemonetics Corporation (HAZ.F)

62.00
+1.00
+(1.64%)
At close: May 16 at 9:39:12 PM GMT+2

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Christopher A. Simon CEO, President & Director 3.22M 9.88M 1964
Mr. James C. D'Arecca CPA CFO, Executive VP & Financial Officer 1.17M -- 1971
Ms. Michelle L. Basil J.D. Executive VP, General Counsel & Secretary 1.11M -- 1972
Mr. Frank W. Chan Ph.D. Executive VP & COO -- -- 1970
Ms. Farris Maryanne Maunsell VP, Chief Accounting Officer & Principal Accounting Officer -- -- 1976
Ms. Olga Guyette Senior Director of Investor Relations -- -- --
Mr. Rajeev Varma Senior Vice President of Strategy & Corporate Development -- -- --
Ms. Laurie A. Miller Senior VP & Chief Human Resources Officer -- -- 1974
Dr. Jan Hartmann M.D. Senior VP & Chief Medical Officer -- -- --
Ms. Kerri DiPietro Senior Vice President of Global Quality Assurance -- -- --

Haemonetics Corporation

125 Summer Street
Boston, MA 02110
United States
781 848 7100 https://www.haemonetics.com
Sector: 
Healthcare
Industry: 
Medical Devices

Description

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Corporate Governance

Haemonetics Corporation’s ISS Governance QualityScore as of May 1, 2025 is 2. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 4; Compensation: 3.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 6, 2025 at 10:00 AM UTC - August 11, 2025 at 10:00 AM UTC

Haemonetics Corporation Earnings Date

Recent Events